AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Inosine triphosphate pyrophosphatase including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Inosine triphosphate pyrophosphatase therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Inosine triphosphate pyrophosphatase, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Inosine triphosphate pyrophosphatase. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Inosine triphosphate pyrophosphatase. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Inosine triphosphate pyrophosphatase includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Inosine triphosphate pyrophosphatase
partner:
Reaxense
upacc:
Q9BY32
UPID:
ITPA_HUMAN
Alternative names:
Non-canonical purine NTP pyrophosphatase; Non-standard purine NTP pyrophosphatase; Nucleoside-triphosphate diphosphatase; Nucleoside-triphosphate pyrophosphatase; Putative oncogene protein hlc14-06-p
Alternative UPACC:
Q9BY32; A2A2N2; A4UIM5; B2BCH7; O14878; Q5JWH4; Q9BYN1; Q9BYX0; Q9H3H8
Background:
Inosine triphosphate pyrophosphatase, known by alternative names such as Non-canonical purine NTP pyrophosphatase, plays a crucial role in hydrolyzing non-canonical purine nucleotides to prevent their incorporation into RNA and DNA, thereby avoiding chromosomal lesions. This enzyme's activity is pivotal in maintaining the integrity of genetic material by excluding non-canonical purines from RNA and DNA precursor pools.
Therapeutic significance:
The enzyme's deficiency is linked to Inosine triphosphate pyrophosphohydrolase deficiency, characterized by abnormal accumulation of inosine triphosphate in erythrocytes, and Developmental and epileptic encephalopathy 35, a severe early-onset epilepsy. Understanding the enzyme's role could lead to novel therapeutic strategies for these conditions, highlighting its potential in drug discovery.
